PT764028E - Metodo para o tratamento de secrecoes pulmonares retidas - Google Patents

Metodo para o tratamento de secrecoes pulmonares retidas

Info

Publication number
PT764028E
PT764028E PT94919422T PT94919422T PT764028E PT 764028 E PT764028 E PT 764028E PT 94919422 T PT94919422 T PT 94919422T PT 94919422 T PT94919422 T PT 94919422T PT 764028 E PT764028 E PT 764028E
Authority
PT
Portugal
Prior art keywords
lantibiotic
subject
treatment
secrections
pulmonary
Prior art date
Application number
PT94919422T
Other languages
English (en)
Inventor
Richard C Boucher Jr
Luis M Molina Y Vedia
Monroe Jackson Stutts
David C Henke
Original Assignee
Univ North Carolina
Molichem Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Molichem Medicines Inc filed Critical Univ North Carolina
Publication of PT764028E publication Critical patent/PT764028E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Steroid Compounds (AREA)
PT94919422T 1993-06-09 1994-06-08 Metodo para o tratamento de secrecoes pulmonares retidas PT764028E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/074,315 US5512269A (en) 1993-06-09 1993-06-09 Method of treating retained pulmonary secretions
PCT/US1994/006486 WO1994028726A2 (en) 1993-06-09 1994-06-08 Method of treating retained pulmonary secretions

Publications (1)

Publication Number Publication Date
PT764028E true PT764028E (pt) 2002-06-28

Family

ID=22118924

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94919422T PT764028E (pt) 1993-06-09 1994-06-08 Metodo para o tratamento de secrecoes pulmonares retidas

Country Status (11)

Country Link
US (5) US5512269A (pt)
EP (2) EP0764028B1 (pt)
JP (2) JP4027968B2 (pt)
AT (1) ATE212854T1 (pt)
AU (1) AU696374B2 (pt)
CA (1) CA2164517C (pt)
DE (1) DE69429832T2 (pt)
DK (1) DK0764028T3 (pt)
ES (1) ES2170769T3 (pt)
PT (1) PT764028E (pt)
WO (1) WO1994028726A2 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
KR19990028283A (ko) * 1995-06-23 1999-04-15 스폰 벤자민 티. 항생제-내성 그람 양성 박테리아의 억제 및 감염 치료 방법
US5910479A (en) * 1996-10-18 1999-06-08 Ambi Inc. Method for the treatment of Streptococcus pneumoniae infection
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
JP4741727B2 (ja) * 1998-05-27 2011-08-10 ユーロ−セルティーク エス．エイ． 抗炎症剤、特に消毒剤及び／又は創傷治癒促進剤を下気道に適用するための製剤
US6323191B1 (en) 1998-06-19 2001-11-27 Genzyme Corporation Small molecule chloride transport
IL140700A0 (en) * 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
CZ20012147A3 (cs) * 1998-12-17 2003-01-15 Chiron Corporation Farmaceutický prostředek ve formě suchého práąku nebo rozpráąeného aerosolového prostředku pro léčení chronické bronchitidy
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US20050147566A1 (en) * 2002-03-12 2005-07-07 Scott Fleming Site specific delivery of co-administered drugs via inhalation
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7378386B2 (en) 2002-07-15 2008-05-27 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
US7511124B2 (en) * 2002-07-15 2009-03-31 Board Of Regents, The University Of Texas System Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7879801B2 (en) * 2002-07-15 2011-02-01 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
EP2283869A3 (en) 2002-07-15 2012-06-27 Board of Regents, The University of Texas System Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
US7828739B2 (en) * 2002-08-27 2010-11-09 Precision Pulsus, Inc. Apnea detection system
US6869402B2 (en) * 2002-08-27 2005-03-22 Precision Pulsus, Inc. Method and apparatus for measuring pulsus paradoxus
US7199230B2 (en) * 2002-10-10 2007-04-03 Molichem Medicines, Inc. Nucleic acids encoding duramycin
EP1560540A4 (en) * 2002-10-18 2008-03-19 Molichem Medicines Inc METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS
DE10261782A1 (de) * 2002-12-19 2004-07-01 Dr. Petry Genmedics Gmbh Neue Gene und Genprodukte
WO2004080427A2 (en) * 2003-03-12 2004-09-23 Schneider Daniel J Method of preventing and treating infections that attack mucosa and assisting rehabilitation thereafter using topically applied ascorbic acid
CA2520028A1 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
EP1750740A4 (en) * 2004-05-06 2009-06-10 Molichem Medicines Inc TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
CN101146545B (zh) * 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
AU2006297289B2 (en) * 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
JP2009521481A (ja) * 2005-12-21 2009-06-04 ナイトロックス， エルエルシー 安定なｓ−ニトロソチオール製剤
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
WO2007092582A2 (en) * 2006-02-08 2007-08-16 Biosynexus Incorporated Neutralization of bacterial spores
AU2007243184A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
CN103990111B (zh) * 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
WO2009141264A2 (en) * 2008-05-20 2009-11-26 Boehringer Ingelheim Vetmedica Gmbh Gallidermin to treat infections of the respiratory tract
MX2011007313A (es) 2009-01-14 2011-08-04 Novacta Biosystems Ltd Derivados de desoxiactagardina.
SG173504A1 (en) 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
US8991390B2 (en) 2010-01-05 2015-03-31 Microdose Therapeutx, Inc. Inhalation device and method
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2014099676A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
EP3428153A1 (en) 2012-12-17 2019-01-16 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683072A (en) * 1968-03-14 1972-08-08 William J Miller A methobottromycin and process for treating poultry infections
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6234923A (ja) * 1985-08-09 1987-02-14 Hitachi Ltd 新規な重合体
EP0257956B2 (en) * 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
ATE101490T1 (de) * 1988-06-22 1994-03-15 Applied Microbiology Inc Nisin-zusammensetzungen zur anwendung als erhoehte breit-spektrum-bakterizide.
US5135910A (en) * 1988-06-22 1992-08-04 The Public Health Research Institute Of The City Of New York Nisin compositions for use as enhanced, broad range bactericides
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
DE3938140A1 (de) * 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
CA2108455C (en) * 1991-04-15 1999-01-19 Peter J. Edwards Pharmaceutical compositions against gastric disorders
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis

Also Published As

Publication number Publication date
ATE212854T1 (de) 2002-02-15
JP4027968B2 (ja) 2007-12-26
WO1994028726A2 (en) 1994-12-22
ES2170769T3 (es) 2002-08-16
DK0764028T3 (da) 2002-03-18
DE69429832D1 (de) 2002-03-21
EP1166794A2 (en) 2002-01-02
EP1166794A3 (en) 2003-03-12
US5651957A (en) 1997-07-29
EP0764028A2 (en) 1997-03-26
US5512269A (en) 1996-04-30
CA2164517C (en) 2010-01-19
US5716931A (en) 1998-02-10
AU7057894A (en) 1995-01-03
US5683675A (en) 1997-11-04
US5849706A (en) 1998-12-15
EP0764028B1 (en) 2002-02-06
JP2005206612A (ja) 2005-08-04
DE69429832T2 (de) 2002-08-14
WO1994028726A3 (en) 1995-03-02
CA2164517A1 (en) 1994-12-22
JPH09501413A (ja) 1997-02-10
AU696374B2 (en) 1998-09-10

Similar Documents

Publication Publication Date Title
PT764028E (pt) Metodo para o tratamento de secrecoes pulmonares retidas
EP0754069A4 (en) METHOD OF TREATING PULMONARY VASOCONSTRICTION AND ASTHMA
EA200100338A1 (ru) Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента
DK0656206T3 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
GB9425160D0 (en) Medicaments
CA2146954A1 (en) Breath activated nicotine inhalers
ES2082732T1 (es) Dispositivos para tratar la vasoconstriccion pulmonar y el asma.
EP0682526A4 (en) LENGTH ADMINISTRATION OF SCR1 AND OTHER COMPLEMENT INHIBITORS.
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
MX9605650A (es) Formulaciones de propionato de fluticasona.
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
HUP9902675A2 (hu) Fluorozott-szénhidrogén-hajtógázt tartalmazó mometazon-furoát aeroszol
GR3022083T3 (en) Inhalant based on taurine
BR0006237A (pt) Inalador em aerossol, e, processo de tratamentode um sujeito com um agente farmacêutico
van der Schans Physiotherapy and bronchial mucus transport